Business, Health Care, Local News

European Medicines Agency validates Bristol Myers Squibb’s application for zeposia (ozanimod) for the treatment of ulcerative colitis

Marketing Authorization Application is supported by positive results from the pivotal Phase 3 True North study evaluating oral Zeposia (ozanimod) in adults with moderately to severely active ulcerative colitis If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for